Umaimainthan Palendira Selected Research

Immunotherapy

4/2024	Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.
1/2024	CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses.
1/2023	Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy.
11/2022	Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis.
1/2022	Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.
1/2022	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
3/2021	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies.
1/2021	The tumour immune landscape and its implications in cutaneous melanoma.
11/2020	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab.
11/2019	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Umaimainthan Palendira Research Topics

Disease

10	Neoplasms (Cancer) 01/2024 - 11/2013
9	Melanoma (Melanoma, Malignant) 04/2024 - 01/2018
7	Tuberculosis (Tuberculoses) 09/2023 - 03/2002
6	Infections 01/2023 - 03/2002
2	Colitis 11/2022 - 11/2020
2	Communicable Diseases (Infectious Diseases) 01/2022 - 08/2013
1	Infectious Mononucleosis (Glandular Fever) 01/2023
1	COVID-19 11/2021
1	Autoimmune Diseases (Autoimmune Disease) 11/2020
1	Erythema 11/2020
1	Edema (Dropsy) 11/2020
1	Epstein-Barr Virus Infections 01/2017
1	Mevalonate Kinase Deficiency 11/2016
1	Immune Reconstitution Inflammatory Syndrome 10/2015
1	Cystitis 10/2015
1	Anti-Glomerular Basement Membrane Disease (Goodpasture's Syndrome) 10/2015
1	Disease Progression 01/2014
1	Job Syndrome (Hyper-IgE Syndrome) 08/2013
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2010
1	Latent Infection 09/2005
1	Pulmonary Tuberculosis 02/2003

Drug/Important Bio-Agent (IBA)

5	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2019
4	AntigensIBA 01/2023 - 04/2002
4	Proteins (Proteins, Gene)FDA Link 11/2020 - 04/2002
3	VaccinesIBA 09/2023 - 02/2003
2	Immune Checkpoint InhibitorsIBA 04/2024 - 01/2022
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 09/2023 - 04/2002
2	IpilimumabIBA 01/2022 - 11/2020
2	LigandsIBA 03/2021 - 10/2010
2	CytokinesIBA 03/2021 - 08/2002
2	DNA (Deoxyribonucleic Acid)IBA 11/2007 - 08/2002
2	Interferon-gamma (Interferon, gamma)IBA 11/2007 - 04/2002
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2024
1	InterferonsIBA 01/2024
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2024
1	Fas Ligand Protein (Fas Ligand)IBA 01/2024
1	PerforinIBA 01/2024
1	ChemokinesIBA 01/2023
1	NivolumabIBA 01/2022
1	COVID-19 VaccinesIBA 11/2021
1	Infliximab (Remicade)FDA Link 11/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2020
1	AntibodiesIBA 11/2020
1	Programmed Cell Death 1 ReceptorIBA 11/2020
1	SteroidsIBA 11/2020
1	Interleukin-15 (Interleukin 15)IBA 01/2018
1	CholesterolIBA 11/2016
1	EnzymesIBA 11/2016
1	rab GTP-Binding ProteinsIBA 11/2016
1	Mevalonic Acid (Mevalonate)IBA 11/2016
1	Rituximab (Mabthera)FDA Link 10/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2015
1	Sirolimus (Rapamycin)FDA Link 01/2014
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 08/2013
1	interleukin-21 (interleukin 21)IBA 08/2013
1	Signaling Lymphocytic Activation Molecule Associated ProteinIBA 10/2010
1	flt3 ligand protein (flt3 ligand)IBA 11/2007
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2007
1	EpitopesIBA 09/2005
1	AerosolsIBA 02/2005
1	Tuberculosis VaccinesIBA 02/2003
1	DNA VaccinesIBA 02/2003
1	IntegrinsIBA 03/2002
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 03/2002

Therapy/Procedure

11	Immunotherapy 04/2024 - 01/2018
9	Therapeutics 01/2023 - 11/2013